Biogen CEO Vounatsos, board and top execs formally agreed to keep the breakup civil

John Carroll

Editor & Founder

If the pleasantries exchanged today between the Biogen board and CEO Michel Vounatsos looked a bit intricately scripted to you, even by corporate PR standards …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biogen CEO Vounatsos, board and top execs formally agreed to keep the breakup civil

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Biotech VC firm outlines plans for $100M fund

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Breaking down silos with a new quantitative approach to drug development

Bio­gen CEO Vounatsos, board and top ex­ecs for­mal­ly agreed to keep the breakup civ­il

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Biogen CEO Vounatsos, board and top execs formally agreed to keep the breakup civil